We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
Turnover
16.03%
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Avg Time Held
5.4
years
Top 10 Avg Time Held
1.7
years
Top 20 Avg Time Held
2.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
901
Employers Holdings
EIG
$906M
| $2.29M | ﹤0.01% |
48,542
+703
| +1% | +$33.9K |
2018 Q4
26 quarters
|
|
902
Upbound Group
UPBD
$959M
| $2.29M | ﹤0.01% |
91,234
-210,857
| -70% | -$4.93M |
2022 Q2
12 quarters
|
|
903
Kyndryl
KD
$2.87B
| $2.29M | ﹤0.01% |
54,571
+6,241
| +13% | +$226K |
2021 Q4
14 quarters
|
|
904
Zymeworks
ZYME
$1.85B
| $2.29M | ﹤0.01% |
182,270
+358
| +0.2% | +$4.26K |
2023 Q4
6 quarters
|
|
905
Peoples Bancorp
PEBO
$1.32B
| $2.29M | ﹤0.01% |
74,901
+2,353
| +3% | +$68.7K |
2016 Q2
36 quarters
|
|
906
Constellation Energy
CEG
$97.4B
| $2.29M | ﹤0.01% |
7,085
+2,714
| +62% | +$718K |
2022 Q1
13 quarters
|
|
907
Markel Group
MKL
$22.6B
| $2.28M | ﹤0.01% |
1,142
-362
| -24% | -$679K |
2016 Q2
36 quarters
|
|
908
Enpro
NPO
$6.01B
| $2.27M | ﹤0.01% |
11,868
-444
| -4% | -$75.9K |
2021 Q1
17 quarters
|
|
909
DELISTED
Sage Therapeutics
SAGE
| $2.25M | ﹤0.01% |
246,804
-945,685
| -79% | -$6.96M |
2024 Q2
4 quarters
|
|
910
Vanguard Morningstar Total Stock Market ETF
VTI
$697B
| $2.25M | ﹤0.01% |
7,403
| – | – |
2024 Q3
3 quarters
|
|
911
Mueller Industries
MLI
$13.4B
| $2.25M | ﹤0.01% |
56,620
-1,078
| -2% | -$40.7K |
2024 Q2
4 quarters
|
|
912
Akebia Therapeutics
AKBA
$193M
| $2.25M | ﹤0.01% |
617,318
-296,131
| -32% | -$814K |
2020 Q2
20 quarters
|
|
913
Macerich
MAC
$6.55B
| $2.24M | ﹤0.01% |
138,222
-263,059
| -66% | -$4.06M |
2019 Q4
22 quarters
|
|
914
Fifth Third Bancorp
FITB
$45.7B
| $2.23M | ﹤0.01% |
54,273
-9,406
| -15% | -$353K |
2013 Q2
48 quarters
|
|
915
Tarsus Pharmaceuticals
TARS
$3.32B
| $2.23M | ﹤0.01% |
55,021
+339
| +0.6% | +$15.3K |
2024 Q4
2 quarters
|
|
916
CareDx
CDNA
$3.45B
| $2.23M | ﹤0.01% |
113,950
-17,911
| -14% | -$318K |
2022 Q2
12 quarters
|
|
917
Manhattan Associates
MANH
$13.2B
| $2.21M | ﹤0.01% |
11,203
+1,024
| +10% | +$186K |
2013 Q2
48 quarters
|
|
918
InMode
INMD
$824M
| $2.2M | ﹤0.01% |
152,233
-197
| -0.1% | -$2.89K |
2021 Q4
14 quarters
|
|
919
NovoCure
NVCR
$1.68B
| $2.19M | ﹤0.01% |
123,072
-97,003
| -44% | -$1.69M |
2023 Q3
7 quarters
|
|
920
DELISTED
TopBuild
BLD
| $2.19M | ﹤0.01% |
6,759
+654
| +11% | +$194K |
2018 Q1
29 quarters
|
|
921
Antero Resources
AR
$11.2B
| $2.18M | ﹤0.01% |
54,020
-3,652
| -6% | -$138K |
2021 Q1
17 quarters
|
|
922
ePlus
PLUS
$2.48B
| $2.14M | ﹤0.01% |
+29,719
| New | +$1.95M |
2025 Q2
0 quarters
|
|
923
Kemper
KMPR
$1.67B
| $2.14M | ﹤0.01% |
33,170
+27,482
| +483% | +$1.7M |
2013 Q2
48 quarters
|
|
924
Valaris
VAL
$5.82B
| $2.13M | ﹤0.01% |
50,609
+47,663
| +1,618% | +$1.79M |
2023 Q1
9 quarters
|
|
925
Codexis
CDXS
$141M
| $2.13M | ﹤0.01% |
872,814
-215,137
| -20% | -$505K |
2022 Q4
10 quarters
|
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.